Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 49

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 49
---
 and is available on the Company’s profile on EDGAR at www.sec.gov and on SEDAR+ at www.sedarplus.ca., and the Plan of Arrangement, which is attached to this Circular and Proxy Statement as Annex E. You should carefully read and consider the entire Agreement and Plan of Arrangement, which are the legal documents that govern the Arrangement, because these documents contain important information about the Arrangement and how it affects you. Additionally, see the section of this Circular and Proxy Statement captioned “The Agreement” for additional and more detailed information regarding the legal documents that govern the Arrangement, including the conditions to completion of the Arrangement and the provisions for terminating or amending the Agreement. In addition, important information about the Company is included in or incorporated by reference into this Circular and Proxy Statement. See the section titled “Where You Can Find More Information.” The Parties to the Arrangement Repare Therapeutics Inc. For information about the Company, see “ Where You Can Find More Information” in this Circular and Proxy Statement. XenoTherapeutics, Inc. XenoTherapeutics, Inc. (the “ Parent”) is a Massachusetts-based 501(c)(3) research foundation focused on advancing xenotransplantation through scientific research, clinical development, and public education. Xeno Acquisition Corp. Xeno Acquisition Corp. (the “ Purchaser”) is a wholly-owned subsidiary of Parent that has been organized in connection with the Arrangement (as defined below) and has not carried on any activities other than entering into the arrangement agreement (the “ Agreement”) and activities in connection therewith, whereby the Purchaser will, among other things, acquire all of the issued and outstanding Common Shares, all as more particularly described in the Circular and Proxy Statement (the “ Arrangement”). XOMA Royalty Corporation XOMA Royalty Corporation (“ XRC”) is a biotech royalty aggregator. XRC has a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercialtherapeutic candidates. Plan of Arrangement The following summarizes the steps which will occur under the Plan of Arrangement on the Effective Date (as defined in the Agreement), if all conditions to the completion of the Arrangement have been satisfied or waived. The following description of steps is qualified in its entirety by reference to the full text of the Plan of Arrangement, attached as Annex E to this Circular and Proxy Statement. Commencing at the Effective Time (as defined in the Agreement), each of the events set